Communiqués CEL-SCI Corporation

Actions

CVM

US1508377066

Recherche biotechnologique et médicale

Temps Différé NYSE 22:00:00 31/08/2026			Varia. 5j.	Varia. 1 janv.
1,620 ^USD	+3,85%		+17,39%	-69,20%

14/08	CEL-SCI Corporation publie ses résultats pour le troisième trimestre et les neuf mois clos le 30 juin 2026	CI
04/08	CEL-SCI Corporation publie une étude confirmant sa stratégie de biomarqueurs pour Multikine et fait état d'un bénéfice de survie dans le cancer de la cavité buccale	CI

Communiqués

17/08	CEL-SCI Reports Fiscal Third Quarter 2026 Results	BU
14/08	Cel-Sci: Fiscal Q3 Earnings Snapshot	AQ
04/08	CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study	BU
30/07	Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients	BU
13/07	CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer	BU
24/06	CEL SCI : and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.-Saudi Cooperation in Cancer Care	PU
24/06	CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care	BU
16/06	CEL-SCI Announces Closing of Offering	BU
16/06	CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy	BU
15/06	CEL-SCI Corporation Announces Pricing of Offering	BU
12/06	CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia	BU
18/05	CEL-SCI Reports Fiscal Second Quarter 2026 Results	BU
15/05	Cel-Sci: Fiscal Q2 Earnings Snapshot	AQ
13/05	CEL-SCI Announces Closing of Public Offering	BU
12/05	CEL-SCI Corporation Announces Pricing of Public Offering	BU
11/05	CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia	BU
18/02	CEL-SCI Reports Fiscal First Quarter 2026 Results	BU
17/02	Cel-Sci: Fiscal Q1 Earnings Snapshot	AQ
29/12	CEL-SCI Reports Fiscal 2025 Results	BU
29/12	CEL SCI : Annual Report for Fiscal Year Ending 09-30, 2025 (Form 10-K)	PU
20/10/25	CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025	NE
10/10/25	CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference	NE
29/08/25	CEL-SCI Announces Closing of $10 Million Public Offering	BU
28/08/25	CEL-SCI Announces Pricing of $10 Million Public Offering	BU
27/08/25	CEL-SCI Announces Proposed Public Offering	BU